Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in Japanese Patients With Episodic Migraine
NCT02959177Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galcanezumab in migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Monthly Migraine Headache Days at Month 6. Started Nov 2016; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02959177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959177.